Kolexia
Orfeuvre Hubert Oncologie médicale
Orfeuvre Hubert
Oncologie médicale
Hôpital Fleyriat
Bourg-en-Bresse, France
94 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Lymphomes Tumeurs de l'ovaire Leucémies Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Métastase tumorale Fatigue Lymphome T

Collaborateurs

Voir plus
Arnaud-Coffin Patrick
Arnaud-Coffin Patrick
Hôpital Fleyriat, Bourg-en-Bresse, France
Rotarski Maciej
Rotarski Maciej
Centre D'oncologie Et De Radiotherapie, Bayonne, France
Assaf Elias
Assaf Elias
Hôpital Henri Mondor, Créteil, France
Lamuraglia Michele
Lamuraglia Michele
Hopital Prive De La Seine Saint Denis, Le Blanc-Mesnil, France

Industries

Voir plus
IQVIA
334 collaboration(s)
Dernière en 2023
A+A
326 collaboration(s)
Dernière en 2023
B3TSI
128 collaboration(s)
Dernière en 2023
Zeste Research
50 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Annals of hematology   06 mars 2024
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer: Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
ABLE02: A National, Multicenter, Randomized Controlled Trial to Assess the Efficacy of a Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Women With Metastatic Breast Cancer
Essai Clinique (Centre Léon-Bérard)   29 août 2023
19P Long term sexual disorders among rare ovarian cancer survivors: The national GINECO case-control Vivrovaire Rare Tumors study
Abstract Book of the ESMO Sarcoma & Rare Cancers 20-22 March 2023, Lugano, Switzerland   01 mars 2023
FASTRACS-RCT: Facilitate and Sustain Return to Work After Breast Cancer: Randomized Controlled Trial
Essai Clinique (Hospices Civils de Lyon)   24 février 2023
FIRE: A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Essai Clinique (Janssen)   05 octobre 2022
535P Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Abstract Book of ESMO Breast Cancer 2022, Berlin, Germany, 03-05 May 2022   01 mai 2022
Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)
2021 San Antonio Breast Cancer Symposium   15 février 2022
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
BMC cancer   26 octobre 2021